Video
LUGPA 2022: Dr. Shore on the significance of genetic testing in prostate cancer
Author(s):
“There’s a lot of clinical utility to genetic testing, and there are familial implications and clinical trial implications,” explains Neal Shore, MD.
Video Player is loading.
Neal Shore, MD, explains how genetic testing has become an essential component of the treatment paradigm for patients with prostate cancer. Shore is co-chairing the CME program at the 2022 LUGPA Annual Meeting, which will include a session on genetic testing. Shore is medical director for the Carolina Urologic Research Center and chief medical officer, Surgical Oncology and Urology, for Genesis Care (US).
Related Videos
Gautam Jayram, MD, on key bladder cancer agents to keep an eye on
Arvin K. George, MD, provides update on the PRESERVE trial
Kari Bailey, MD, on the evolving priorities of women in urology
Andrew Y. Sun, MD, on the role for APPs in men’s health
Gautam Jayram, MD, gives an overview of recently approved agents in NMIBC
Thomas Mueller, MD, on the removal of residual stone fragments
Arvin K. George, MD, on study of water vapor thermal therapy for prostate cancer
Kara Cossis, PA-C, MPH, on challenges, opportunities with genetic testing
Joy Maulik, CRNP, on the growing role of PARP inhibitors in prostate cancer
Jason Hafron, MD, on the importance of patient selection in the new era of bladder cancer treatment
Related Content
